Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, Busse PM, Chan AW, Clark JR, Deschler DG, Emerick KS, Hammon RJ, Wirth LJ, Lin DT, Mroz EA, Faquin WC, Rocco JW.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djy224. [Epub ahead of print]

PMID:
30715409
2.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
3.

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A.

Eur J Cancer. 2019 Jan;106:61-68. doi: 10.1016/j.ejca.2018.10.002. Epub 2018 Nov 22.

4.

Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.

Wirth LJ.

J Clin Endocrinol Metab. 2018 Nov 19. doi: 10.1210/jc.2018-02437. [Epub ahead of print] No abstract available.

PMID:
30462299
5.

Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions?

Park JC, Chan AW, Wirth LJ.

J Oncol Pract. 2018 Oct;14(10):603-605. doi: 10.1200/JOP.18.00529. No abstract available.

PMID:
30312565
6.

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M.

Cancer. 2018 Jun 1;124(11):2365-2372. doi: 10.1002/cncr.31344. Epub 2018 Apr 14.

PMID:
29656442
7.

Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer.

Addison D, Lawler PR, Emami H, Janjua SA, Staziaki PV, Hallett TR, Hennessy O, Lee H, Szilveszter B, Lu M, Mousavi N, Nayor MG, Delling FN, Romero JM, Wirth LJ, Chan AW, Hoffmann U, Neilan TG.

J Stroke. 2018 Jan;20(1):71-79. doi: 10.5853/jos.2017.01802. Epub 2018 Jan 31.

8.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

9.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

PMID:
29301825
10.

PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.

Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng YC, Chen H, Poznansky MC, Iyengar NM, Pai SI.

Cancer Res. 2017 Nov 15;77(22):6365-6374. doi: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25.

11.

Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer.

Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, Szilveszter B, Lu MT, Cambria RP, Hoffmann U, Chan AW, Wirth LJ, Neilan TG.

J Am Heart Assoc. 2017 Aug 30;6(9). pii: e006453. doi: 10.1161/JAHA.117.006453.

12.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

13.

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH.

Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.

14.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.

15.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
16.

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.

Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M.

J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109. Epub 2016 Aug 22.

17.

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S.

Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20.

PMID:
27688102
18.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

19.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.

Cancer. 2016 Dec 15;122(24):3856-3864. doi: 10.1002/cncr.30252. Epub 2016 Aug 15.

20.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ.

Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.

21.

ROS1 Rearrangement in Thyroid Cancer.

Ritterhouse LL, Wirth LJ, Randolph GW, Sadow PM, Ross DS, Liddy W, Lennerz JK.

Thyroid. 2016 Jun;26(6):794-7. doi: 10.1089/thy.2016.0101.

PMID:
27089969
22.

Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.

Wirth LJ.

J Clin Oncol. 2016 Apr 20;34(12):1289-91. doi: 10.1200/JCO.2015.65.1414. Epub 2016 Feb 16. No abstract available.

PMID:
26884569
23.

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

Rothenberg SM, Daniels GH, Wirth LJ.

Clin Cancer Res. 2015 Dec 15;21(24):5640-1. doi: 10.1158/1078-0432.CCR-15-2298. No abstract available.

24.

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.

Lubitz CC, Parangi S, Holm TM, Bernasconi MJ, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ.

J Mol Diagn. 2016 Jan;18(1):100-8. doi: 10.1016/j.jmoldx.2015.08.003. Epub 2015 Nov 26.

25.

New and emerging therapeutic options for thyroid carcinoma: A&A discussion.

Clayman GL, Wirth LJ.

Clin Adv Hematol Oncol. 2015 Apr;13(4 Suppl 4):17. No abstract available.

PMID:
26430871
26.

Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.

Wirth LJ.

Clin Adv Hematol Oncol. 2015 Apr;13(4 Suppl 4):9-16. No abstract available.

PMID:
26430870
27.

DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C.

Semin Radiat Oncol. 2015 Oct;25(4):237-50. doi: 10.1016/j.semradonc.2015.05.007. Epub 2015 May 14. Review.

28.

Anaplastic Thyroid Carcinoma, Version 2.2015.

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

29.

Lenvatinib in radioiodine-refractory thyroid cancer.

Schlumberger M, Tahara M, Wirth LJ.

N Engl J Med. 2015 May 7;372(19):1868. doi: 10.1056/NEJMc1503150. No abstract available.

PMID:
25946295
30.

New frontiers and treatment paradigms for thyroid carcinoma.

Haddad R, Sherman SI, Shah JP, Wirth LJ.

Clin Adv Hematol Oncol. 2014 Jul;12(7 Suppl 14):3-21; quiz 22. Review. No abstract available.

PMID:
25768715
31.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.

N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.

32.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

33.

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.

Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ.

Clin Cancer Res. 2015 Mar 1;21(5):1028-35. doi: 10.1158/1078-0432.CCR-14-2915. Epub 2014 Dec 30.

34.

Thyroid carcinoma, version 2.2014.

Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80; quiz 1680.

PMID:
25505208
35.

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.

Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW.

Clin Cancer Res. 2015 Mar 1;21(5):1002-9. doi: 10.1158/1078-0432.CCR-14-1234. Epub 2014 Dec 12.

36.

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE.

Lung Cancer. 2014 Nov;86(2):241-6. doi: 10.1016/j.lungcan.2014.08.012. Epub 2014 Aug 27.

37.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.

Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE.

Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20.

38.

Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.

Wirth LJ.

Cancer Prev Res (Phila). 2014 Mar;7(3):279-82. doi: 10.1158/1940-6207.CAPR-13-0437. Epub 2014 Jan 17.

39.

Long-term survival after distant metastasis in patients with oropharyngeal cancer.

McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW.

Oral Oncol. 2014 Mar;50(3):208-12. doi: 10.1016/j.oraloncology.2013.10.020. Epub 2013 Dec 31.

PMID:
24387975
40.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.

41.

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ.

Head Neck. 2014 Aug;36(8):1181-8. doi: 10.1002/hed.23430. Epub 2014 Mar 10.

42.

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.

Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI, Stephenson JJ Jr, Wirth LJ, McCoy S, Hei YJ, Hsu CP, Tebbutt NC.

BMC Cancer. 2013 May 16;13:242. doi: 10.1186/1471-2407-13-242.

43.

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL Jr.

Cancer Prev Res (Phila). 2013 May;6(5):410-8. doi: 10.1158/1940-6207.CAPR-13-0004.

44.

Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.

Wirth LJ, Ross DS, Randolph GW, Cunnane ME, Sadow PM.

N Engl J Med. 2013 Feb 14;368(7):664-73. doi: 10.1056/NEJMcpc1210080. No abstract available.

PMID:
23406032
45.

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ.

Thyroid. 2013 Apr;23(4):392-407. doi: 10.1089/thy.2012.0520. Review.

PMID:
23294230
46.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

47.

Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer.

Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC.

N Engl J Med. 2012 Sep 20;367(12):1136-47. No abstract available.

PMID:
22992078
48.

Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.

Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW.

Anticancer Res. 2012 May;32(5):1743-6.

PMID:
22593455
49.

Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease.

Houvras Y, Wirth LJ.

J Clin Oncol. 2011 Jul 1;29(19):2616-8. doi: 10.1200/JCO.2010.34.0505. Epub 2011 May 23. No abstract available.

PMID:
21606409
50.

Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.

Sher DJ, Balboni TA, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1405-11. doi: 10.1016/j.ijrobp.2010.04.029. Epub 2010 Dec 20.

PMID:
21177045

Supplemental Content

Loading ...
Support Center